Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles P Hart

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Oncotarget|July 5, 2016
Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapyChanghwan Yoon, Kevin K Chang, Jun Ho Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2013
Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia modelsScott Portwood, Deepika Lal, Yung-Chun Hsu, et al.
American Journal of Cancer Research|September 2, 2015
Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma modelsJessica D Sun, Dharmendra Ahluwalia, Qian Liu, et al.
Cancer Biology & Therapy|February 14, 2015
Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancerJessica D Sun, Qian Liu, Dharmendra Ahluwalia, et al.
Translational Oncology|August 5, 2017
A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor ModelCarla Hajj, James Russell, Charles P Hart, et al.
Cancer Research|May 25, 2018
Metabolic and Physiologic Imaging Biomarkers of the Tumor Microenvironment Predict Treatment Outcome with Radiation or a Hypoxia-Activated Prodrug in MiceShingo Matsumoto, Shun Kishimoto, Keita Saito, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2011
Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancerJessica D Sun, Qian Liu, Jingli Wang, et al.
Plos One|December 23, 2014
Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancerKate M Bailey, Heather H Cornnell, Arig Ibrahim-Hashim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2024
Correction: Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of CancerJessica D Sun, Qian Liu, Jingli Wang, et al.
Blood|June 10, 2010
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrugJinsong Hu, Damian R Handisides, Els Van Valckenborgh, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Oncotarget|July 5, 2016
Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapyChanghwan Yoon, Kevin K Chang, Jun Ho Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2013
Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia modelsScott Portwood, Deepika Lal, Yung-Chun Hsu, et al.
American Journal of Cancer Research|September 2, 2015
Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma modelsJessica D Sun, Dharmendra Ahluwalia, Qian Liu, et al.
Cancer Biology & Therapy|February 14, 2015
Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancerJessica D Sun, Qian Liu, Dharmendra Ahluwalia, et al.
Translational Oncology|August 5, 2017
A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor ModelCarla Hajj, James Russell, Charles P Hart, et al.
Cancer Research|May 25, 2018
Metabolic and Physiologic Imaging Biomarkers of the Tumor Microenvironment Predict Treatment Outcome with Radiation or a Hypoxia-Activated Prodrug in MiceShingo Matsumoto, Shun Kishimoto, Keita Saito, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2011
Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancerJessica D Sun, Qian Liu, Jingli Wang, et al.
Plos One|December 23, 2014
Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancerKate M Bailey, Heather H Cornnell, Arig Ibrahim-Hashim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2024
Correction: Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of CancerJessica D Sun, Qian Liu, Jingli Wang, et al.
Blood|June 10, 2010
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrugJinsong Hu, Damian R Handisides, Els Van Valckenborgh, et al.
Pageof 4